584 Shares in HCA Healthcare, Inc. (NYSE:HCA) Bought by San Luis Wealth Advisors LLC

11 Oct 2024, 18:42 by Mitch Edgeman · The Markets Daily

San Luis Wealth Advisors LLC acquired a new stake in HCA Healthcare, Inc. (NYSE:HCA – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 584 shares of the company’s stock, valued at approximately $237,000.

Several other hedge funds have also added to or reduced their stakes in HCA. Massmutual Trust Co. FSB ADV grew its stake in shares of HCA Healthcare by 7.4% in the third quarter. Massmutual Trust Co. FSB ADV now owns 421 shares of the company’s stock worth $171,000 after purchasing an additional 29 shares during the last quarter. Brookstone Capital Management raised its position in shares of HCA Healthcare by 0.7% during the third quarter. Brookstone Capital Management now owns 4,065 shares of the company’s stock worth $1,652,000 after acquiring an additional 30 shares during the last quarter. UMB Bank n.a. increased its position in HCA Healthcare by 2.4% during the 3rd quarter. UMB Bank n.a. now owns 1,301 shares of the company’s stock valued at $529,000 after purchasing an additional 30 shares during the period. Lake Street Advisors Group LLC boosted its stake in shares of HCA Healthcare by 1.3% in the 2nd quarter. Lake Street Advisors Group LLC now owns 2,732 shares of the company’s stock valued at $878,000 after purchasing an additional 35 shares during the last quarter. Finally, Financial Counselors Inc. raised its stake in HCA Healthcare by 1.4% during the first quarter. Financial Counselors Inc. now owns 2,642 shares of the company’s stock worth $881,000 after buying an additional 36 shares during the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Stock Up 0.2 %

HCA Healthcare stock opened at $387.25 on Friday. HCA Healthcare, Inc. has a fifty-two week low of $215.96 and a fifty-two week high of $409.42. The firm’s 50-day simple moving average is $386.39 and its 200 day simple moving average is $347.16. The company has a debt-to-equity ratio of 27.11, a quick ratio of 0.94 and a current ratio of 1.06. The stock has a market cap of $99.94 billion, a PE ratio of 18.18, a price-to-earnings-growth ratio of 1.44 and a beta of 1.67.

HCA Healthcare (NYSE:HCA – Get Free Report) last issued its quarterly earnings results on Tuesday, July 23rd. The company reported $5.50 EPS for the quarter, topping analysts’ consensus estimates of $4.97 by $0.53. The business had revenue of $17.49 billion for the quarter, compared to analyst estimates of $17.05 billion. HCA Healthcare had a return on equity of 553.13% and a net margin of 8.40%. HCA Healthcare’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $4.29 earnings per share. Research analysts predict that HCA Healthcare, Inc. will post 22.51 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 16th were given a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend was Monday, September 16th. HCA Healthcare’s dividend payout ratio is currently 12.39%.

Insider Buying and Selling

In other HCA Healthcare news, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the sale, the executive vice president now directly owns 29,678 shares in the company, valued at $11,438,494.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, EVP Michael S. Cuffe sold 8,358 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $385.42, for a total value of $3,221,340.36. Following the sale, the executive vice president now owns 29,678 shares of the company’s stock, valued at $11,438,494.76. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Kathleen M. Whalen sold 2,987 shares of HCA Healthcare stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $363.51, for a total transaction of $1,085,804.37. Following the completion of the transaction, the senior vice president now owns 9,454 shares of the company’s stock, valued at $3,436,623.54. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 17,202 shares of company stock valued at $6,407,273. 1.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

HCA has been the subject of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $392.00 price objective on shares of HCA Healthcare in a research report on Tuesday, October 1st. Barclays increased their price target on HCA Healthcare from $376.00 to $396.00 and gave the stock an “overweight” rating in a report on Wednesday, July 24th. Oppenheimer increased their target price on shares of HCA Healthcare from $345.00 to $390.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. KeyCorp started coverage on shares of HCA Healthcare in a report on Friday. They set an “overweight” rating and a $475.00 price objective on the stock. Finally, Royal Bank of Canada boosted their target price on HCA Healthcare from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Friday, August 23rd. Five analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $365.65.

Get Our Latest Research Report on HCA Healthcare

HCA Healthcare Company Profile

(Free Report)